SLC5A2 and diabetes mellitus: One of the benefits of SGLT2 inhibitor treatment in patients with type 2 diabetes mellitus is the weight loss associated with this class of drugs, a study showed weight loss change versus placebo was -1.3 to -2.0 kg [11].